Mark Roschewski, MD

Dr. Roschewski is the Clinical Director of Lymphoid Malignancies within the Center for Cancer Research, National Cancer Institute in Bethesda, MD. Dr. Roschewski’s research team conducts clinical trials with a strong translational emphasis in a variety of aggressive lymphomas including diffuse large B-cell lymphoma (DLBCL), primary CNS lymphoma (PCNSL), mantle cell lymphoma, Burkitt lymphoma, and EBV-associated lymphomas. Recent studies from this translational research team have established dose-adjusted EPOCH-R as a standard therapy for primary mediastinal B-cell lymphoma, HIV-associated DLBCL, and Burkitt lymphoma. Further, the team has demonstrated that ibrutinib, the first inhibitor of Bruton’s tyrosine kinase (Btk), has clinical activity in both ABC-DLBCL and PCNSL; findings that have led to changes in treatment paradigms.

Dr. Roschewski’s personal research focus includes the clinical and research applications of monitoring circulating tumor DNA (ctDNA) as an early biomarker that identifies early treatment failure, clonal evolution, and disease relapse in lymphomas. Dr. Roschewski also leads a variety of clinical trials for patients with follicular lymphoma (FL) at initial diagnosis as well as relapse with a focus on defining high-risk groups that benefit most frome innovative treatment approaches.

AREAS OF EXPERTISE

Circulating tumor DNA (ctDNA) as a biomarker in lymphoma; biology and treatment of follicular lymphoma, diffuse large B-cell lymphoma, primary CNS lymphoma, Burkitt lymphoma, mantle cell lymphoma, and EBV-associated lymphomas